Letter in Response to Oral and Transdermal Rivastigmine for the Treatment of Anticholinergic Delirium: A Case Report

We read with interest the article “Oral and Transdermal Rivastigmine for the Treatment of Anticholinergic Delirium: A Case Report” by Fratta et al. (1). Using a rivastigmine dosing approach similar to that described in the article, we successfully managed a case of diphenhydramine-associated antimuscarinic toxicity with 13.8 mg of transdermal rivastigmine (0.15 mg/kg). Whereas the ultimate management of our patient with transdermal rivastigmine followed the dosing strategy within this case report, we describe here additional pertinent factors that we considered in the use of transdermal rivastigmine for antimuscarinic toxi city (1).
Source: The Journal of Emergency Medicine - Category: Emergency Medicine Authors: Tags: Letter to the Editor Source Type: research